The MedicalXpress article 'Not just boys: The overlooked story of ADHD in women and girls' correctly challenges the stereotype of the hyperactive classroom boy by describing inattentive girls who daydream, chatty students who cannot finish assignments, and chronically disorganized mothers. However, it stops short of analyzing the deeper structural causes and long-term consequences of this diagnostic gap.

A 2014 narrative review by Quinn and Madhoo (Primary Care Companion CNS Disord, N not applicable as review, no declared conflicts of interest) synthesized data from multiple observational cohorts and concluded that girls with ADHD are diagnosed at significantly lower rates than boys because their symptoms more often present as internal restlessness and inattention rather than external hyperactivity. The review notes that DSM criteria were largely derived from male-dominated samples.

This finding is reinforced by a large-scale Swedish registry-based observational study (Rydell et al., 2018, sample size approximately 1.2 million children and adults, no pharmaceutical funding) which showed a 3:1 male-to-female diagnosis ratio in childhood that narrows dramatically in adulthood, indicating thousands of girls are missed during critical developmental windows.

Mainstream coverage routinely misses the connection to broader patterns of sex-biased medical research. Just as early cardiac studies focused on male 'classic' chest pain and overlooked women's subtler symptoms, ADHD research has suffered from male-centric sampling. Most randomized controlled trials of stimulant medications include female participants at rates below 35 percent, with inadequate stratification by sex or menstrual cycle phase, limiting generalizability.

The consequences are substantial: undiagnosed women experience higher rates of comorbid anxiety, depression, and low self-esteem. A 2023 meta-analysis of 23 observational studies (total N>50,000) found women with ADHD face elevated risk of emotional dysregulation and functional impairment across the lifespan. Hormonal fluctuations across the menstrual cycle, pregnancy, and menopause further modulate symptom severity, an area almost entirely absent from clinical guidelines.

The original piece also fails to address how this bias intersects with race and socioeconomic status, where minority girls face even steeper barriers to evaluation. Addressing the gap requires sex-specific diagnostic tools, physician education on female presentations, and research mandates that demand adequate female enrollment with prespecified sex-disaggregated analyses.